Prevalence of valvular-regurgitation associated with dexfenfluramine three to five months after discontinuation of treatment. (Q52917335)

9 May 2018

title

Prevalence of valvular-regurgitation associated with dexfenfluramine three to five months after discontinuation of treatment. (English)

1 reference

9 May 2018

author name string

Weissman NJ

1

1 reference

9 May 2018

Tighe JF Jr

2

1 reference

9 May 2018

Gottdiener JS

3

1 reference

9 May 2018

Gwynne JT

4

1 reference

9 May 2018

language of work or name

English

0 references

publication date

1 December 1999

1 reference

9 May 2018

Journal of the American College of Cardiology

published in

1 reference

9 May 2018

volume

34

1 reference

9 May 2018

issue

7

1 reference

9 May 2018

page(s)

2088-2095

1 reference

9 May 2018

Valvular heart disease associated with fenfluramine-phentermine

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900445-3

7 January 2021

The fen-phen finale: a study of weight loss and valvular heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900445-3

7 January 2021

Valvular heart disease associated with fenfluramine-phentermine

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900445-3

7 January 2021

Asymptomatic mitral and aortic valve disease is seen in half of the patients taking 'phen-fen'.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900445-3

7 January 2021

Valve disease associated with chronic intake of fenfluramines

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900445-3

7 January 2021

An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900445-3

7 January 2021

Color Doppler assessment of mitral regurgitation with orthogonal planes

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900445-3

7 January 2021

Evaluation of aortic insufficiency by Doppler color flow mapping

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900445-3

7 January 2021

Morphology of the human mitral valve. II. The value leaflets

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900445-3

7 January 2021

Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900445-3

7 January 2021

Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study)

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900445-3

7 January 2021

A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900445-3

7 January 2021

Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900445-3

7 January 2021

ACC/AHA guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association. Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Dise

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900445-3

7 January 2021

10.1016/S0735-1097(99)00445-3

Identifiers

DOI

1 reference

9 May 2018

PubMed ID

10588229

1 reference

9 May 2018